Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
NCT04169074 · University of Arizona · PHASE2 · terminated · last registry update 2026-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Standard of care therapy for Stage III-IVA HNSCC updated in June to include neoadjuvant + adjuvant immunotherapy.” | – | Registry record, University of Arizona |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Results posted on the registry: Mayo Clinic, Abemaciclib (NCT03979508)
- 2026-11-02Also stopped (terminated): Mayo Clinic, Abemaciclib (NCT03979508)
- 2026-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, Abemaciclib + PI3K Inhibitor paxalisib (NCT03994796)
- 2026-10-27Also stopped (terminated): Pfizer, ARV-471 + Ribociclib (NCT05573555)
- 2026-10-26Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., HRS-6209 + Letrozole + Dalpciclib/Palbociclib + Letrozole/Anastrozole (NCT07894328)
- 2026-10-21Also stopped (terminated): Novartis Pharmaceuticals, JDQ443 + trametinib (NCT05358249)
- 2026-10-19Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., Trilaciclib + Etoposide Injection (NCT07881705)
- 2026-10-15Results posted on the registry: Praful Ravi, MB BCHir, MRCP, Darolutamide + Abemaciclib (NCT05617885)
- 2026-10-15Also stopped (terminated): Praful Ravi, MB BCHir, MRCP, Darolutamide + Abemaciclib (NCT05617885)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-10-07Results posted on the registry: Pfizer, Palbociclib + Temozolomide (NCT03709680)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Pre-operative abemaciclib + abemaciclib + temozolomide (NCT05413304)
- 2026-09-29Results posted on the registry: Arvinas Estrogen Receptor, Inc., Vepdegestrant + Vepdegestrant (NCT04072952)
- 2026-09-25Results posted on the registry: Stephen Bagley, MD, MSCE, Abemaciclib 200 MG (NCT03969706)
- 2026-09-25Results posted on the registry: Memorial Sloan Kettering Cancer Center, Fulvestrant + Abemaciclib (NCT03643510)
- 2026-09-24Results posted on the registry: Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-24Also stopped (terminated): Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-14Results posted on the registry: Baylor Research Institute, Abemaciclib + Ramucirumab (NCT04921904)
- 2026-09-04Results posted on the registry: University of Utah, Ribociclib + Belinostat (NCT04315233)
- 2026-09-04Also stopped (terminated): University of Utah, Ribociclib + Belinostat (NCT04315233)
- 2026-09-03Phase 3 first posted: SWOG Cancer Research Network, NSAI + CDK4/6i + NSAI + CDK4/6i + Capivasertib (NCT07802626)
- 2026-08-17Results posted on the registry: University of Leicester, Rucaparib + Abemaciclib (NCT03654833)
- 2026-07-22Also stopped (terminated): M.D. Anderson Cancer Center, Everolimus + Neratinib (NCT03065387)
- 2026-07-21Phase 3 first posted: UNICANCER, a drug against CDK4 (NCT07717450)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision